<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172118</url>
  </required_header>
  <id_info>
    <org_study_id>1222.35</org_study_id>
    <nct_id>NCT02172118</nct_id>
  </id_info>
  <brief_title>BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of Single Dose of BI 1744 CL (30 μg Administered With the Respimat® Inhaler) in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open Label, Parallel Group Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the influence of severe renal impairment on the pharmacokinetics (PK),
      safety, and selected pharmacodynamic (PD) parameters of BI 1744 CL (30 μg administered by
      inhalation with the Respimat® Inhaler)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-4 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 4 hours after dosing)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma at different time points)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (percentage of area under the concentration-time curve obtained by extrapolation)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time of the analyte in the body after inhalation)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to t2)</measure>
    <time_frame>before and at 0-8, 8-12, 12-24, 24-48, 48-72 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of analyte excreted in urine from the time point t1 to t2)</measure>
    <time_frame>before and at 0-8, 8-12, 12-24, 24-48, 48-72 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte in plasma from the time point t1 to t2)</measure>
    <time_frame>before and at 0-8, 8-12, 12-24, 24-48, 48-72 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma protein binding of BI 1744 BS</measure>
    <time_frame>before and at 0:05, 0:10, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00, 48:00, 72:00 hours following drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability on a 4-point scale by the investigator</measure>
    <time_frame>within 5 to 14 days after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>severely renally impaired patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1774 CL</intervention_name>
    <arm_group_label>severely renally impaired patients</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects:

          -  Healthy male and female subjects determined by results of screening with a creatinine
             clearance &gt;80 mL/min (Treatment Group 2)

          -  Age 21 - 75 years

          -  Body Mass Index (BMI) &gt;=18.5 and &lt;=32 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Renally impaired subjects:

          -  Renally impaired male or female subjects (Treatment Group 1) determined by results of
             screening with the following creatinine clearance as estimated according to
             Cockroft-Gault: Creatinine clearance &lt;30 mL/min (Treatment Group 1, Renal Function
             Group 4)

          -  Age 21 - 75 years

          -  BMI &gt;=18.5 and &lt;=34 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

        Healthy subjects who meet any of the following criteria will not be entered into this
        trial:

          -  Any finding of the medical examination (including blood pressure (BP) [&gt;140 mmHg
             systolic and or &gt;95 mmHg diastolic], pulse rate (PR) and electrocardiogram (ECG))
             deviating from normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Relevant gastrointestinal tract surgery (except appendectomy, herniotomy)

          -  Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric
             disorders or neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections (e.g. including Hepatitis B and C and HIV)

          -  History of allergy/hypersensitivity (including drug allergies) that are deemed
             relevant to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Participation in another trial with an investigational drug within one month after
             previous single dose administration or two months after previous multiple dose
             administration prior to administration or during the trial

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking when confined to the study site on trial days

          -  Alcohol abuse (more than 40 g/day in males, more than 20 g/day in females)

          -  Drug abuse, in the investigator's judgement upon review of the patient's history and
             urine screening for abused substances

          -  Veins unsuited for iv puncture on either arm (e.g. veins which are difficult to
             locate, access or puncture, veins with a tendency to rupture during or after puncture)

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within 48 hours prior to trial or during the trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  Subjects not able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

        Renally impaired subjects who meet any of the following criteria will not be entered into
        this trial:

          -  Moderate and severe concurrent liver function impairment (e.g. due to hepatorenal
             syndrome)

          -  Patients with significant diseases other than renal impairment will be excluded. A
             significant disease is defined as a disease which in the opinion of the investigator

               -  put the patient at risk because of participation in the study

               -  may influence the results of the study

               -  may influence the patient's ability to participate in the study

               -  is not in a stable condition

                    -  Diabetic or hypertensive patients can be entered in this trial if the
                       disease is not significant according to these criteria.

          -  Relevant gastrointestinal tract surgery (except appendectomy, herniotomy)

          -  Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric
             disorders or neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections (e.g. including Hepatitis B and C and HIV)

          -  History of allergy/hypersensitivity (including drug allergies) that are deemed
             relevant to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial,
             excluded are those drugs, the patient is currently taking for treatment of the renal
             or concomitant disease

          -  Subjects with a change of their chronic medication less than 4 weeks prior to dosing

          -  Participation in another trial with an investigational drug within one month after
             previous single dose administration or two months after previous multiple dose
             administration prior to administration or during the trial

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking when confined to the study site on trial days

          -  Alcohol abuse (more than 40 g/day in males, more than 20 g/day in females)

          -  Drug abuse, in the investigator's judgement upon review of the patient's history and
             urine screening for abused substances

          -  Veins unsuited for iv puncture on either arm (e.g. veins which are difficult to
             locate, access or puncture, veins with a tendency to rupture during or after puncture)

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within 48 hours prior to trial or during the trial)

          -  Clinically relevant laboratory abnormalities (except for renal function tests or
             deviations of clinical laboratory values that are related to renal impairment)

          -  Hemoglobin &lt; 8 g/dL indicating severe renal anemia (use of erythropoetin is allowed to
             maintain hematocrit)

          -  Inability to comply with dietary regimen of study centre

          -  Subjects not able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions

          -  Systolic blood pressure &lt; 100 or &gt; 180 mm Hg, diastolic blood pressure &lt; 60 or &gt; 110
             mm Hg, pulse rate &lt; 50 or &gt; 100 1/min

        Exclusion criteria specific for this study due to the known class side effect profile of
        ß2- mimetics (healthy or renally impaired subjects):

          -  Asthma or history of pulmonary hyperreactivity

          -  Hyperthyrosis

          -  Allergic rhinitis in need of treatment

          -  Clinically relevant cardiac arrhythmia

        For female subjects (healthy or renally impaired):

          -  Pregnancy or planning to become pregnant within 2 months of study completion

          -  Positive pregnancy test

          -  No adequate contraception in women of childbearing potential (adequate contraception:
             e.g. sterilisation, intrauterine device or oral contraception not containing ethinyl
             estradiol or ethinyl estradiol with an additional barrier method) for at least 3
             months prior to participation in the study

          -  Inability to maintain this adequate contraception during the whole trial period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

